25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Medexus Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Medexus together

I guess you are interested in Medexus Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Medexus Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Medexus Pharmaceuticals Inc

I send you an email if I find something interesting about Medexus Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Medexus (30 sec.)










1.2. What can you expect buying and holding a share of Medexus? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$1.91
Expected worth in 1 year
C$2.55
How sure are you?
35.0%

+ What do you gain per year?

Total Gains per Share
C$0.64
Return On Investment
13.5%

For what price can you sell your share?

Current Price per Share
C$4.75
Expected price per share
C$3.27 - C$
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Medexus (5 min.)




Live pricePrice per Share (EOD)
C$4.75
Intrinsic Value Per Share
C$2.18 - C$7.48
Total Value Per Share
C$4.09 - C$9.39

2.2. Growth of Medexus (5 min.)




Is Medexus growing?

Current yearPrevious yearGrowGrow %
How rich?$32.7m$20.5m$10.7m34.2%

How much money is Medexus making?

Current yearPrevious yearGrowGrow %
Making money$573.9k$1.2m-$653.2k-113.8%
Net Profit Margin2.1%4.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Medexus (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Medexus?

Welcome investor! Medexus's management wants to use your money to grow the business. In return you get a share of Medexus.

First you should know what it really means to hold a share of Medexus. And how you can make/lose money.

Speculation

The Price per Share of Medexus is C$4.75. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Medexus.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Medexus, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$1.91. Based on the TTM, the Book Value Change Per Share is C$0.16 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.07 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Medexus.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps0.000.1%0.020.5%0.051.0%-0.08-1.6%-0.05-1.1%
Usd Book Value Change Per Share0.010.1%0.112.3%0.051.0%0.010.3%0.030.6%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.010.1%0.112.3%0.051.0%0.010.3%0.030.6%
Usd Price Per Share1.84-1.49-1.49-2.26-1.52-
Price to Earnings Ratio103.22-24.11--1.16-1.92--0.22-
Price-to-Total Gains Ratio294.90-87.59-10.42-5.01-0.87-
Price to Book Ratio1.39-1.17-1.83-3.96-2.95-
Price-to-Total Gains Ratio294.90-87.59-10.42-5.01-0.87-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share3.30315
Number of shares302
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.110.01
Usd Total Gains Per Share0.110.01
Gains per Quarter (302 shares)33.704.01
Gains per Year (302 shares)134.8016.04
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101351250166
2027026003222
3040439504838
4053953006454
5067466508070
6080980009686
709449350112102
80107810700128118
90121312050144134
100134813400160150

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%5.07.00.041.7%6.014.00.030.0%9.031.00.022.5%9.041.00.018.0%
Book Value Change Per Share4.00.00.0100.0%6.06.00.050.0%9.011.00.045.0%14.026.00.035.0%18.032.00.036.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.050.00.0%
Total Gains per Share4.00.00.0100.0%6.06.00.050.0%9.011.00.045.0%14.026.00.035.0%18.032.00.036.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Medexus Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0090.160-94%0.070-87%0.019-53%0.040-78%
Book Value Per Share--1.9101.827+5%1.201+59%1.245+53%0.857+123%
Current Ratio--1.0121.081-6%0.803+26%1.096-8%2.863-65%
Debt To Asset Ratio--0.7750.794-2%0.872-11%0.847-8%0.742+4%
Debt To Equity Ratio--3.4403.880-11%6.914-50%7.055-51%4.444-23%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value---96683376.000-113309619.750+17%-127134501.750+31%-78296870.737-19%-30511802.862-68%
Eps--0.0060.033-81%0.072-91%-0.108+1785%-0.074+1253%
Ev To Ebitda Ratio--infinfnan%-4.413nan%infnan%infnan%
Ev To Sales Ratio---0.639-0.753+18%-0.743+16%-0.537-16%0.236-371%
Free Cash Flow Per Share--0.2520.283-11%0.190+33%0.036+604%0.005+5041%
Free Cash Flow To Equity Per Share---0.064-0.140+119%0.176-136%0.065-199%0.087-173%
Gross Profit Margin--1.0001.259-21%0.869+15%1.773-44%1.848-46%
Intrinsic Value_10Y_max--7.480--------
Intrinsic Value_10Y_min--2.179--------
Intrinsic Value_1Y_max--0.596--------
Intrinsic Value_1Y_min--0.054--------
Intrinsic Value_3Y_max--1.908--------
Intrinsic Value_3Y_min--0.305--------
Intrinsic Value_5Y_max--3.361--------
Intrinsic Value_5Y_min--0.712--------
Market Cap117099375.000+44%65329125.00052694718.750+24%52941243.750+23%80034341.250-18%53964322.500+21%
Net Profit Margin--0.0040.021-80%0.043-90%-0.086+2159%-0.241+5852%
Operating Margin---0.072-100%0.103-100%-0.0060%-0.3660%
Operating Ratio--1.3070.994+31%0.879+49%1.006+30%1.328-2%
Pb Ratio2.486+44%1.3871.172+18%1.835-24%3.960-65%2.946-53%
Pe Ratio185.009+44%103.21524.109+328%-1.157+101%1.924+5266%-0.224+100%
Price Per Share4.750+44%2.6502.138+24%2.148+23%3.247-18%2.189+21%
Price To Free Cash Flow Ratio4.713+44%2.6292.616+1%0.382+588%-8.984+442%-5.041+292%
Price To Total Gains Ratio528.596+44%294.90187.587+237%10.420+2730%5.006+5791%0.874+33626%
Quick Ratio--0.2060.368-44%0.407-49%0.568-64%2.193-91%
Return On Assets--0.0010.004-81%0.007-90%-0.012+1673%-0.050+6696%
Return On Equity--0.0030.018-81%0.047-93%-0.226+6816%-0.226+6833%
Total Gains Per Share--0.0090.160-94%0.070-87%0.019-53%0.040-78%
Usd Book Value--32751899.47931313670.852+5%20592853.079+59%21351736.077+53%14690440.870+123%
Usd Book Value Change Per Share--0.0060.112-94%0.049-87%0.013-53%0.028-78%
Usd Book Value Per Share--1.3291.270+5%0.835+59%0.866+53%0.596+123%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value---67233619.670-78795509.574+17%-88409332.517+31%-54447643.910-19%-21217907.710-68%
Usd Eps--0.0040.023-81%0.050-91%-0.075+1785%-0.051+1253%
Usd Free Cash Flow--4319437.4624852864.981-11%3249331.342+33%613989.075+604%84024.043+5041%
Usd Free Cash Flow Per Share--0.1750.197-11%0.132+33%0.025+604%0.003+5041%
Usd Free Cash Flow To Equity Per Share---0.044-0.098+119%0.123-136%0.045-199%0.061-173%
Usd Market Cap81430905.375+44%45429873.52536643907.419+24%36815340.904+23%55655880.905-18%37526789.867+21%
Usd Price Per Share3.303+44%1.8431.486+24%1.493+23%2.258-18%1.522+21%
Usd Profit--110036.619573941.001-81%1227158.385-91%-1550375.823+1509%-1116131.626+1114%
Usd Revenue--26311756.26926198468.568+0%29821174.165-12%22823632.809+15%13107355.011+101%
Usd Total Gains Per Share--0.0060.112-94%0.049-87%0.013-53%0.028-78%
 EOD+4 -4MRQTTM+15 -22YOY+18 -195Y+18 -1810Y+20 -16

3.3 Fundamental Score

Let's check the fundamental score of Medexus Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15185.009
Price to Book Ratio (EOD)Between0-12.486
Net Profit Margin (MRQ)Greater than00.004
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.206
Current Ratio (MRQ)Greater than11.012
Debt to Asset Ratio (MRQ)Less than10.775
Debt to Equity Ratio (MRQ)Less than13.440
Return on Equity (MRQ)Greater than0.150.003
Return on Assets (MRQ)Greater than0.050.001
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Medexus Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5073.062
Ma 20Greater thanMa 503.833
Ma 50Greater thanMa 1003.081
Ma 100Greater thanMa 2002.810
OpenGreater thanClose4.000
Total4/5 (80.0%)

4. In-depth Analysis

4.1 About Medexus Pharmaceuticals Inc

Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery. The company's products portfolio also includes Cuvposa, a glycopyrrolate oral solution; Naproxen, a Pediapharm naproxen suspension; Otixal, a ciprofloxacin and flucinolone acetonide; Trispan, a triamcinolone hexacetonide injectable suspension; and Trecondyv, a bifunctional alkylating agent for use as part of a conditioning treatment for patients undergoing allogeneic hematopoietic stem cell transplantation. In addition, it offers over the counter products comprising Nyda, a topical revolutionary treatment indicated for the eradication of head lice; Relaxa, an osmotic laxative to treat occasional constipation in adults; Oralvisc to reduce joint pain and enhance joint function in osteoarthritis of the knee; and Calcia Calcium and vitamin D products. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Toronto, Canada.

Fundamental data was last updated by Penke on 2025-01-10 06:43:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Medexus earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.4% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.4%. The company is not making a profit/loss.
  • The TTM is 2.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ0.4%TTM2.1%-1.7%
TTM2.1%YOY4.3%-2.2%
TTM2.1%5Y-8.6%+10.7%
5Y-8.6%10Y-24.1%+15.4%
4.3.1.2. Return on Assets

Shows how efficient Medexus is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.1% Return on Assets means that Medexus generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.1%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.4%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.1%TTM0.4%-0.3%
TTM0.4%YOY0.7%-0.3%
TTM0.4%5Y-1.2%+1.6%
5Y-1.2%10Y-5.0%+3.8%
4.3.1.3. Return on Equity

Shows how efficient Medexus is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Equity means Medexus generated $0.00 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM1.8%-1.4%
TTM1.8%YOY4.7%-2.9%
TTM1.8%5Y-22.6%+24.3%
5Y-22.6%10Y-22.6%+0.1%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Medexus Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Medexus is operating .

  • Measures how much profit Medexus makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM7.2%-7.2%
TTM7.2%YOY10.3%-3.1%
TTM7.2%5Y-0.6%+7.9%
5Y-0.6%10Y-36.6%+36.0%
4.3.2.2. Operating Ratio

Measures how efficient Medexus is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.31 means that the operating costs are $1.31 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 1.307. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.994. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.307TTM0.994+0.313
TTM0.994YOY0.879+0.115
TTM0.9945Y1.006-0.012
5Y1.00610Y1.328-0.322
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Medexus Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Medexus is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.01 means the company has $1.01 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 1.012. The company is just able to pay all its short-term debts.
  • The TTM is 1.081. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.012TTM1.081-0.070
TTM1.081YOY0.803+0.279
TTM1.0815Y1.096-0.015
5Y1.09610Y2.863-1.767
4.4.3.2. Quick Ratio

Measures if Medexus is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.21 means the company can pay off $0.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.206. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.368. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.206TTM0.368-0.162
TTM0.368YOY0.407-0.039
TTM0.3685Y0.568-0.200
5Y0.56810Y2.193-1.625
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Medexus Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Medexus assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Medexus to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.77 means that Medexus assets are financed with 77.5% credit (debt) and the remaining percentage (100% - 77.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 0.775. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.794. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.775TTM0.794-0.019
TTM0.794YOY0.872-0.078
TTM0.7945Y0.847-0.053
5Y0.84710Y0.742+0.105
4.5.4.2. Debt to Equity Ratio

Measures if Medexus is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 344.0% means that company has $3.44 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Medexus Pharmaceuticals Inc:

  • The MRQ is 3.440. The company is unable to pay all its debts with equity. -1
  • The TTM is 3.880. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ3.440TTM3.880-0.440
TTM3.880YOY6.914-3.034
TTM3.8805Y7.055-3.175
5Y7.05510Y4.444+2.612
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Medexus generates.

  • Above 15 is considered overpriced but always compare Medexus to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 103.22 means the investor is paying $103.22 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Medexus Pharmaceuticals Inc:

  • The EOD is 185.009. Based on the earnings, the company is expensive. -2
  • The MRQ is 103.215. Based on the earnings, the company is expensive. -2
  • The TTM is 24.109. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD185.009MRQ103.215+81.793
MRQ103.215TTM24.109+79.107
TTM24.109YOY-1.157+25.266
TTM24.1095Y1.924+22.185
5Y1.92410Y-0.224+2.147
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Medexus Pharmaceuticals Inc:

  • The EOD is 4.713. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 2.629. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 2.616. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD4.713MRQ2.629+2.084
MRQ2.629TTM2.616+0.014
TTM2.616YOY0.382+2.233
TTM2.6165Y-8.984+11.600
5Y-8.98410Y-5.041-3.943
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Medexus is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Medexus Pharmaceuticals Inc:

  • The EOD is 2.486. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.387. Based on the equity, the company is underpriced. +1
  • The TTM is 1.172. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.486MRQ1.387+1.099
MRQ1.387TTM1.172+0.216
TTM1.172YOY1.835-0.663
TTM1.1725Y3.960-2.789
5Y3.96010Y2.946+1.015
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets145,367
Total Liabilities112,626
Total Stockholder Equity32,741
 As reported
Total Liabilities 112,626
Total Stockholder Equity+ 32,741
Total Assets = 145,367

Assets

Total Assets145,367
Total Current Assets64,198
Long-term Assets81,169
Total Current Assets
Cash And Cash Equivalents 6,973
Net Receivables 13,050
Inventory 38,167
Other Current Assets 388
Total Current Assets  (as reported)64,198
Total Current Assets  (calculated)58,578
+/- 5,620
Long-term Assets
Property Plant Equipment 731
Goodwill 10,295
Intangible Assets 61,328
Long-term Assets  (as reported)81,169
Long-term Assets  (calculated)72,354
+/- 8,815

Liabilities & Shareholders' Equity

Total Current Liabilities63,447
Long-term Liabilities49,179
Total Stockholder Equity32,741
Total Current Liabilities
Short Long Term Debt 17,759
Accounts payable 37,117
Other Current Liabilities 2,674
Total Current Liabilities  (as reported)63,447
Total Current Liabilities  (calculated)57,550
+/- 5,897
Long-term Liabilities
Long term Debt 25,215
Long-term Liabilities  (as reported)49,179
Long-term Liabilities  (calculated)25,215
+/- 23,964
Total Stockholder Equity
Total Stockholder Equity (as reported)32,741
Total Stockholder Equity (calculated)0
+/- 32,741
Other
Capital Stock76,721
Common Stock Shares Outstanding 24,526
Net Debt 36,001
Net Invested Capital 75,715
Net Working Capital 751
Property Plant and Equipment Gross 1,972



6.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-31
> Total Assets 
438
592
536
551
541
502
484
460
7,760
6,666
5,536
4,436
7,156
6,222
5,200
4,442
5,896
7,375
6,763
6,319
5,795
9,023
8,926
7,850
7,168
6,889
7,070
82,619
85,009
87,301
85,348
85,224
122,811
125,249
121,589
138,049
148,513
142,970
137,210
138,131
139,225
136,399
142,308
146,320
161,329
166,874
166,178
160,377
155,733
147,262
145,367
145,367147,262155,733160,377166,178166,874161,329146,320142,308136,399139,225138,131137,210142,970148,513138,049121,589125,249122,81185,22485,34887,30185,00982,6197,0706,8897,1687,8508,9269,0235,7956,3196,7637,3755,8964,4425,2006,2227,1564,4365,5366,6667,760460484502541551536592438
   > Total Current Assets 
438
592
536
551
541
502
484
460
7,103
5,888
4,716
3,068
5,998
5,065
3,946
3,238
4,548
6,047
5,414
4,856
4,201
7,194
7,051
6,007
5,138
4,949
4,897
37,097
35,059
36,974
35,768
36,588
40,044
43,465
40,966
56,994
58,571
47,886
43,918
46,595
49,111
48,385
56,686
61,886
72,969
79,503
79,479
74,080
72,496
65,452
64,198
64,19865,45272,49674,08079,47979,50372,96961,88656,68648,38549,11146,59543,91847,88658,57156,99440,96643,46540,04436,58835,76836,97435,05937,0974,8974,9495,1386,0077,0517,1944,2014,8565,4146,0474,5483,2383,9465,0655,9983,0684,7165,8887,103460484502541551536592438
       Cash And Cash Equivalents 
364
576
536
551
541
502
484
460
5,733
5,006
3,943
2,346
5,363
4,452
3,066
2,415
3,807
5,024
3,887
3,062
2,430
4,499
4,008
3,686
2,794
2,484
2,169
21,210
21,873
20,867
19,170
17,308
5,235
7,484
6,403
9,351
18,704
10,199
8,137
9,571
10,018
7,285
9,647
9,273
13,069
15,782
19,501
8,213
5,255
8,454
6,973
6,9738,4545,2558,21319,50115,78213,0699,2739,6477,28510,0189,5718,13710,19918,7049,3516,4037,4845,23517,30819,17020,86721,87321,2102,1692,4842,7943,6864,0084,4992,4303,0623,8875,0243,8072,4153,0664,4525,3632,3463,9435,0065,733460484502541551536576364
       Short-term Investments 
0
0
0
0
51
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000000000510000
       Net Receivables 
0
0
0
0
0
0
0
0
976
608
437
366
237
263
479
336
231
302
585
554
479
1,034
979
780
572
943
921
10,735
7,442
10,817
10,105
11,468
14,962
16,679
14,375
26,122
18,829
17,037
14,083
14,689
14,407
14,715
17,017
20,323
22,381
25,946
22,659
22,227
24,030
13,249
13,050
13,05013,24924,03022,22722,65925,94622,38120,32317,01714,71514,40714,68914,08317,03718,82926,12214,37516,67914,96211,46810,10510,8177,44210,7359219435727809791,03447955458530223133647926323736643760897600000000
       Other Current Assets 
0
0
0
0
0
0
0
0
11
30
19
17
107
48
43
26
41
69
91
57
13
31
54
48
77
139
317
1,669
1,506
1,355
2,333
1,857
1,413
1,461
1,594
1,431
1,665
1,402
1,344
1,511
1,280
1,103
1,084
1,176
2,295
2,314
2,246
2,346
2,301
388
388
3883882,3012,3462,2462,3142,2951,1761,0841,1031,2801,5111,3441,4021,6651,4311,5941,4611,4131,8572,3331,3551,5061,6693171397748543113579169412643481071719301100000000
   > Long-term Assets 
0
0
0
0
652
0
0
0
657
778
819
1,368
1,158
1,157
1,254
1,204
1,348
1,329
1,349
1,463
1,594
1,829
1,876
1,842
2,031
1,940
2,174
45,521
49,950
50,327
49,580
48,636
82,767
81,784
80,625
81,076
89,942
95,084
93,292
91,536
90,114
88,014
85,622
84,434
88,360
87,371
86,699
86,297
83,237
81,810
81,169
81,16981,81083,23786,29786,69987,37188,36084,43485,62288,01490,11491,53693,29295,08489,94281,07680,62581,78482,76748,63649,58050,32749,95045,5212,1741,9402,0311,8421,8761,8291,5941,4631,3491,3291,3481,2041,2541,1571,1581,3688197786570006520000
       Property Plant Equipment 
0
0
0
0
19
0
0
0
21
31
66
59
47
46
38
33
31
27
25
21
17
17
17
17
16
14
13
550
649
1,459
1,354
1,243
1,099
1,019
958
870
795
1,407
1,336
1,252
1,221
1,125
1,021
953
899
875
894
843
778
747
731
7317477788438948758999531,0211,1251,2211,2521,3361,4077958709581,0191,0991,2431,3541,45964955013141617171717212527313338464759663121000190000
       Goodwill 
0
0
0
0
0
0
0
0
-41
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,992
7,048
7,025
7,830
10,061
10,226
10,317
10,572
10,653
10,730
10,585
10,611
10,686
10,527
10,221
10,278
10,282
10,390
10,286
10,396
10,276
10,227
10,295
10,29510,22710,27610,39610,28610,39010,28210,27810,22110,52710,68610,61110,58510,73010,65310,57210,31710,22610,0617,8307,0257,0486,9920000000000000000000-4100000000
       Intangible Assets 
0
0
0
0
631
0
0
0
675
747
754
1,304
1,111
1,111
1,216
1,171
1,317
1,302
1,324
1,443
1,577
1,812
1,859
1,826
2,015
1,926
2,161
44,451
41,788
41,287
40,676
39,041
69,487
68,424
67,239
67,518
76,362
80,815
79,268
77,927
76,565
74,811
72,936
71,618
70,373
69,172
67,602
66,391
64,141
62,720
61,328
61,32862,72064,14166,39167,60269,17270,37371,61872,93674,81176,56577,92779,26880,81576,36267,51867,23968,42469,48739,04140,67641,28741,78844,4512,1611,9262,0151,8261,8591,8121,5771,4431,3241,3021,3171,1711,2161,1111,1111,3047547476750006310000
       Other Assets 
0
0
0
0
-652
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,888
-3
-21
2,132
2,132
2,103
1,746
1,642
1,551
1,444
1,585
6,806
6,934
7,917
0
0
0
0
00007,9176,9346,8061,5851,4441,5511,6421,7462,1032,1322,132-21-32,8880000000000000000000000000000-6520000
> Total Liabilities 
47
16
0
0
17
0
0
2
1,841
493
531
436
3,614
3,760
3,480
3,598
3,734
4,024
3,934
4,244
4,823
4,981
4,912
4,630
4,816
5,067
7,938
40,608
57,136
61,391
59,153
62,255
98,531
104,987
102,997
133,743
130,495
131,497
113,220
114,989
121,433
118,836
125,361
130,892
138,881
144,147
144,437
130,815
125,410
114,675
112,626
112,626114,675125,410130,815144,437144,147138,881130,892125,361118,836121,433114,989113,220131,497130,495133,743102,997104,98798,53162,25559,15361,39157,13640,6087,9385,0674,8164,6304,9124,9814,8234,2443,9344,0243,7343,5983,4803,7603,6144365314931,84120017001647
   > Total Current Liabilities 
47
16
0
0
17
0
0
2
1,302
486
525
435
788
838
747
923
721
928
812
1,110
1,581
1,565
1,228
891
1,451
1,678
4,378
11,709
10,593
13,320
13,541
17,430
34,171
36,316
32,842
48,025
39,937
42,299
43,075
46,639
48,108
49,703
64,752
100,806
83,496
90,580
94,013
66,477
66,229
59,236
63,447
63,44759,23666,22966,47794,01390,58083,496100,80664,75249,70348,10846,63943,07542,29939,93748,02532,84236,31634,17117,43013,54113,32010,59311,7094,3781,6781,4518911,2281,5651,5811,1108129287219237478387884355254861,30220017001647
       Short-term Debt 
0
0
0
0
9
0
0
0
5
1
0
4
3
3
2
1
0
0
0
0
0
0
0
0
15
15
15
0
0
341
346
351
10,195
9,999
10,833
17,025
10,569
16,375
12,860
18,231
15,046
19,559
29,698
65,177
42,706
47,483
48,358
15,078
15,743
16,572
0
016,57215,74315,07848,35847,48342,70665,17729,69819,55915,04618,23112,86016,37510,56917,02510,8339,99910,19535134634100151515000000001233401500090000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,195
9,999
10,833
17,025
10,569
16,375
12,860
18,231
15,046
19,559
29,698
65,177
42,706
47,483
48,358
15,078
15,743
16,572
17,759
17,75916,57215,74315,07848,35847,48342,70665,17729,69819,55915,04618,23112,86016,37510,56917,02510,8339,99910,19500000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
0
0
0
0
0
0
0
0
700
618
800
270
799
682
985
973
1,437
1,093
756
569
1,536
4,232
11,324
3,004
4,456
13,031
16,426
8,906
23,454
20,444
28,127
14,855
23,319
26,926
24,307
12,046
25,421
28,875
27,683
10,158
34,846
34,783
43,354
7,750
35,440
37,117
37,11735,4407,75043,35434,78334,84610,15827,68328,87525,42112,04624,30726,92623,31914,85528,12720,44423,4548,90616,42613,0314,4563,00411,3244,2321,5365697561,0931,4379739856827992708006187000000000000000
       Other Current Liabilities 
0
0
0
0
-261
0
0
0
1,191
406
522
429
785
136
127
122
450
129
130
125
607
128
136
134
867
127
131
385
7,589
8,523
164
652
15,071
2,863
1,565
2,873
14,513
2,605
3,289
3,132
2,635
3,138
2,682
4,130
2,700
3,220
3,516
2,747
2,703
2,686
2,674
2,6742,6862,7032,7473,5163,2202,7004,1302,6823,1382,6353,1323,2892,60514,5132,8731,5652,86315,0716521648,5237,5893851311278671341361286071251301294501221271367854295224061,191000-2610000
   > Long-term Liabilities 
0
0
0
0
8,415
0
0
0
539
7
6
1
2,826
2,921
2,733
2,675
3,013
3,096
3,123
3,133
3,242
3,416
3,683
3,740
3,365
3,390
3,560
28,899
46,544
48,071
45,613
44,825
64,360
68,671
70,154
85,719
90,558
89,198
70,145
68,350
73,325
69,133
60,609
30,086
55,385
53,567
50,424
64,338
59,181
55,439
49,179
49,17955,43959,18164,33850,42453,56755,38530,08660,60969,13373,32568,35070,14589,19890,55885,71970,15468,67164,36044,82545,61348,07146,54428,8993,5603,3903,3653,7403,6833,4163,2423,1333,1233,0963,0132,6752,7332,9212,8261675390008,4150000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
33,761
34,303
35,331
34,532
34,766
39,816
37,948
30,871
484
27,377
25,440
23,730
0
0
0
0
000023,73025,44027,37748430,87137,94839,81634,76634,53235,33134,30333,76100000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
52,911
52,052
66,530
56,255
53,867
35,613
33,584
33,509
31,185
29,738
29,602
28,008
28,127
0
0
0
0
0
0000028,12728,00829,60229,73831,18533,50933,58435,61353,86756,25566,53052,05252,911000000000000000000000000000000000
> Total Stockholder Equity
392
576
536
551
523
502
483
458
5,919
6,173
5,004
4,000
3,542
2,463
1,720
844
2,162
3,352
2,828
2,076
972
4,042
4,015
3,219
2,352
1,822
-867
42,010
27,873
25,910
26,195
22,969
24,281
20,262
18,592
4,306
18,018
11,473
23,990
23,142
17,792
17,563
16,947
15,428
22,448
22,727
21,741
29,562
30,323
32,587
32,741
32,74132,58730,32329,56221,74122,72722,44815,42816,94717,56317,79223,14223,99011,47318,0184,30618,59220,26224,28122,96926,19525,91027,87342,010-8671,8222,3523,2194,0154,0429722,0762,8283,3522,1628441,7202,4633,5424,0005,0046,1735,919458483502523551536576392
   Common Stock
0
562
551
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,393
46,683
45,453
45,230
42,186
43,809
44,701
47,212
66,688
66,752
67,776
68,668
68,686
68,689
68,797
68,962
69,014
69,117
69,204
76,390
76,390
76,391
0
076,39176,39076,39069,20469,11769,01468,96268,79768,68968,68668,66867,77666,75266,68847,21244,70143,80942,18645,23045,45346,68346,39300000000000000000000000005515620
   Retained Earnings -62,175-62,285-64,242-65,004-64,470-63,377-64,028-70,884-69,377-66,647-65,249-59,962-58,812-68,957-62,370-49,890-34,778-32,600-28,040-28,830-26,614-27,338-25,265-24,118-24,397-21,217-21,072-20,718-20,190-18,999-17,691-16,519-16,091-15,704-16,764-16,789-16,394-16,962-15,350-15,146-14,748-14,317-12,414-191-153-156-150-129-123-950
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,041
9,795
10,219
10,155
9,497
10,081
10,696
10,135
10,384
10,684
10,835
10,960
11,307
11,465
10,913
0
0
0
0
000010,91311,46511,30710,96010,83510,68410,38410,13510,69610,0819,49710,15510,2199,7957,04100000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
392
109
107
680
673
658
636
649
18,333
20,490
19,752
19,146
18,892
19,425
18,114
17,633
18,926
19,055
18,919
18,595
18,662
23,041
24,205
23,937
23,424
23,039
23,529
64,973
5,691
6,205
6,561
6,489
6,630
7,172
7,634
7,964
9,497
10,081
10,696
10,135
10,384
10,684
10,835
10,960
11,307
11,465
10,913
11,880
12,005
12,366
0
012,36612,00511,88010,91311,46511,30710,96010,83510,68410,38410,13510,69610,0819,4977,9647,6347,1726,6306,4896,5616,2055,69164,97323,52923,03923,42423,93724,20523,04118,66218,59518,91919,05518,92617,63318,11419,42518,89219,14619,75220,49018,333649636658673680107109392



6.3. Balance Sheets

Currency in USD. All numbers in thousands.




6.4. Cash Flows

Currency in USD. All numbers in thousands.




6.5. Income Statements

Currency in USD. All numbers in thousands.